ALIM - Alimera Sciences, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
7.05
+0.17 (+2.47%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close6.88
Open6.99
Bid6.75 x 900
Ask8.50 x 800
Day's Range6.86 - 7.48
52 Week Range0.00 - 9.98
Volume103,304
Avg. Volume278,990
Market Cap34.994M
Beta (5Y Monthly)2.11
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
Press Releases
  • GlobeNewswire

    Alimera Sciences Refinances Its Debt Facility With Solar Capital

    The amount of the new funding includes an initial tranche of $42.5 million used to repay the current facility, including principal, prepayment fees and accrued interest, and another $2.5 million tranche that will be available if Alimera achieves $30.0 million in revenue for any trailing six-month period ending on or before November 30, 2020. The interest-only period may be extended an additional six months if Alimera achieves $34.5 million in revenue for any trailing six-month period ending on or before June 30, 2022. “We are pleased that Solar Capital has agreed to extend our relationship and continue working with Alimera in support of our future growth,” said Rick Eiswirth, Alimera’s president and chief executive officer.

  • PR Newswire

    Almira Sciences, Inc 13D filing

    Ronald L Chez, a private investor, files a 13D for Alimera Sciences, Inc. (NASDAQ: ALIM). Alimera returns to growth in the 3rd quarter and expects continued progress in the 4th quarter. The Company is in a strong position to succeed with their unique approach to DME.

  • GlobeNewswire

    Alimera Sciences to Participate in the LD Micro 12th Annual Main Event on December 10, 2019

    Mr. Eiswirth will provide an overview of the company’s business model and growth strategy and will be available for one-on-one meetings. For those interested in attending or for registered attendees who wish to request meetings, please contact David Scher at david@ldmicro.com or visit www.ldmicro.com for more information.

  • GlobeNewswire

    Alimera Announces Regulatory Approval for ILUVIEN® in Benelux Countries for The Treatment of Non-Infectious Posterior Uveitis

    The complete Benelux approval was achieved when The Netherlands’ Medicines Evaluation Board informed Alimera of their approval on November 6, 2019. The approval by Belgium’s Federal Agency for Medicines and Health Products was received in May of 2019, and Luxembourg’s Heads of Medicines Agencies provided its confirmation of regulatory approval in late October.

  • GlobeNewswire

    Alimera Sciences to Participate in the 31st Annual Piper Jaffray Healthcare Conference

    ATLANTA, Nov. 26, 2019 -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera” or “Company”), a leader in the commercialization and development of prescription ophthalmology.

  • GlobeNewswire

    Alimera Sciences Announces Effectiveness of Previously Announced Reverse Stock Split

    The certificate of amendment provides that the reverse stock split will become effective at 5:01 PM Eastern Time today, after the close of trading on The Nasdaq Global Market. Alimera, founded in June 2003, is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals for the management of retinal diseases.

  • GlobeNewswire

    Alimera Sciences Terminates Equity Purchase Agreement

    Alimera Sciences, Inc. (ALIM) (“Alimera”), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that it has terminated its $20.0 million common stock purchase agreement with Lincoln Park Capital Fund, LLC (“LPC”), effective November 12, 2019. “After assessing our expectations for the remainder of this year and plans for 2020, we have made the decision to terminate our equity purchase agreement. Having completed the third quarter of 2019 at an annualized revenue run rate in excess of $50 million, we believe we have sufficient cash on hand to fund our operations throughout 2020,” said Rick Eiswirth, president and CEO of Alimera.

  • GlobeNewswire

    Alimera Sciences Announces Board’s Approval of Reverse Stock Split Ratio

    Alimera Sciences, Inc. (ALIM) (“Alimera”), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that it will effect a one-for-15 reverse stock split (reverse split) of its common stock that will become effective on November 14, 2019 after the close of trading on The Nasdaq Global Market. The reverse split is primarily intended to bring Alimera into compliance with the minimum bid price requirement for maintaining its listing on The Nasdaq Global Market.

  • GlobeNewswire

    Alimera Sciences to Participate in the 10th Annual Craig-Hallum Alpha Select Conference in New York

    Alimera Sciences, Inc. (ALIM) (“Alimera” or “Company”), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, today announces that Rick Eiswirth, President and Chief Executive Officer of Alimera, and Phil Jones, the Company’s Chief Financial Officer, will participate in the 10th Annual Craig-Hallum Alpha Select Conference in New York City on November 12, 2019. The Conference will be held at the Sheraton New York Times Square Hotel 8:00AM-4:40PM Eastern Time.

  • GlobeNewswire

    Alimera Sciences Announces Third Quarter 2019 Financial Results and Provides Corporate Update

    Third Quarter and Recent Company Highlights: Consolidated Net Revenue Up 16% Compared to Third Quarter 2018International Net Revenue Up 62% Compared to Third Quarter 2018Launch.

  • GlobeNewswire

    Alimera Sciences Announces Equity Purchase Agreement for up to $20 Million with Lincoln Park Capital

    Upon entering into the agreement, LPC purchased $1.0 million of Alimera’s registered common stock at $0.50 per share, which represents a 35% premium to the closing market price of the stock on October 24, 2019. Thereafter and upon satisfaction of the conditions in the agreement, Alimera, from time to time over a 36-month period, will have the right, in its sole discretion, to sell up to an additional $19.0 million of its common stock to LPC.

  • GlobeNewswire

    Alimera Sciences to Report Third Quarter 2019 Financial Results on Tuesday, October 29, 2019 and Provide Corporate Update

    Alimera Sciences, Inc. (ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that it will report third quarter 2019 financial results on Tuesday, October 29, 2019 after the market close. For more information, please visit www.alimerasciences.com.

  • GlobeNewswire

    Alimera Obtains Marketing Authorization for ILUVIEN® in Portugal for the Treatment of Non-Infectious Posterior Uveitis

    Alimera Sciences, Inc. (ALIM) (“Alimera”), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that INFARMED, the governmental agency that oversees the availability of medical products in Portugal, granted marketing authorization on October 1, 2019 for ILUVIEN® for the prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment (NIPU). Alimera will market the product directly to physicians in Portugal through its European sales organization. Alimera currently sells ILUVIEN in Portugal for the treatment of diabetic macular edema (DME).

  • GlobeNewswire

    Alimera Sciences Announces Top Line Revenue Expectation For the Third Quarter of 2019

    Alimera Sciences, Inc. (ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, today announces top-line revenue guidance for the quarter ended September 30, 2019. Alimera expects to report consolidated net revenue for the third quarter of 2019 exceeding $12.8 million. This compares to $10.9 million for the second quarter of 2019 and $11.1 million in the third quarter of 2018.

  • GlobeNewswire

    Alimera Sciences Announces Clinical Data Featuring the Benefits of ILUVIEN® to be Presented at the American Academy of Ophthalmology Annual Meeting

    Alimera Sciences, Inc. (ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that clinical data for ILUVIEN® (fluocinolone acetonide intravitreal implant 0.19mg) will be featured in multiple papers and discussions at the Annual Meeting of the American Academy of Ophthalmology, taking place at the Moscone Center in San Francisco from October 12-15, 2019. “We are pleased to once again showcase the differentiated benefits of ILUVIEN for the treatment of DME in several new clinical papers and discussions at this year’s AAO conference,” said Rick Eiswirth, CEO of Alimera.

  • GlobeNewswire

    Alimera Announces Expansion of Agreement with Distribution Partner Horus Pharma to Include Marketing ILUVIEN® in Benelux Countries

    Alimera Sciences, Inc. (ALIM) (“Alimera”), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that it has expanded its relationship with Horus Pharma, one of the Company’s current distributors of ILUVIEN® in Europe.

  • GlobeNewswire

    Alimera Sciences Board of Directors Approves Reverse Stock Split and 10b5-1 Stock Purchase Plan for U.S. Executive Management

    Alimera Sciences, Inc. (ALIM) (“Alimera”), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, today announced that its board of directors has approved a proposal to effect a reverse stock split of its common stock. The reverse stock split is expected to result in a higher per share price and a corresponding lower number of total shares issued and outstanding, which should enable Alimera to attain the minimum $1.00 per share bid price requirement for its common stock as required for continued listing on the Nasdaq Global Market. Alimera believes that a reverse stock split can help increase the marketability of its stock to a broader range of potential investors.

  • GlobeNewswire

    Alimera Sciences Launches ILUVIEN® in Germany For Non-Infectious Uveitis Indication

    Alimera Sciences, Inc. (ALIM) (“Alimera”), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that it will immediately commence the launch of ILUVIEN in Germany for the prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIPU). Following the European Union’s Mutual Recognition Procedure in March 2019, Germany is the second country in Europe in which ILUVIEN is now commercially available to be prescribed to patients suffering from NIPU, a disease with no sustained treatment options.

  • GlobeNewswire

    Alimera Announces ILUVIEN® Regulatory Approval in Australia for the Treatment of Diabetic Macular Edema

    Alimera Sciences, Inc. (ALIM) (“Alimera”), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces today that the Australian Therapeutic Goods Administration (TGA), the division of the Australian Department of Health that oversees the availability of medical products, has approved ILUVIEN® (190 micrograms intravitreal implant in applicator) for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure.

  • GlobeNewswire

    Alimera Sciences Announces Second Quarter 2019 Financial Results and Provides Corporate Update

    Second Quarter and Recent Company Highlights: Consolidated Net Revenue Up 2% Compared to Second Quarter 2018International Net Revenue Up 21% Compared to Second Quarter.

  • GlobeNewswire

    Alimera Sciences Announces Multiple Papers “On Demand” at the 2019 American Society of Retina Specialists Annual Meeting

    Alimera Sciences, Inc. (ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that clinical data for ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19mg, will be featured in four papers “on demand” as part of the 2019 American Society of Retina Specialists (ASRS) Annual Meeting being held July 26-30, 2019 at the Hyatt Regency in Chicago.

  • GlobeNewswire

    Alimera Sciences to Report Second Quarter Financial Results on Monday, July 29, 2019 and Provide Corporate Update

    Alimera Sciences, Inc. (ALIM) (“Alimera” or the “Company”), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, announces that it will report second quarter 2019 financial results on Monday, July 29, 2019 after the market close. Management will host a conference call at 9:00 AM ET on Tuesday, July 30, 2019 to review financial results and provide an update on corporate developments.  Following management’s formal remarks, there will be a question and answer session. Please note that registered participants will receive their dial-in number upon registration and will dial directly into the call without delay.  Those without Internet access or who are unable to pre-register may dial in by calling 1-866-777-2509 (domestic) or 1-412-317-5413 (international).  All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to be joined into the Alimera Sciences call.

  • GlobeNewswire

    Alimera Sciences Announces the Appointment of Industry Veteran and Ophthalmology Business Executive John Snisarenko to its Board of Directors

    Alimera Sciences, Inc. (ALIM) (“Alimera”), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces the appointment of John Snisarenko to its Board of Directors. Mr. Snisarenko has more than 30 years of commercial experience in the pharmaceutical industry, including major retina and ophthalmology businesses.

  • GlobeNewswire

    Alimera’s ILUVIEN® Receives Positive NICE Recommendation for Non-Infectious Posterior Uveitis

    Alimera Sciences, Inc. (ALIM) (“Alimera”), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that the United Kingdom's National Institute for Health and Care Excellence (NICE), in its Final Appraisal Determination for national reimbursement, has recommended funding for ILUVIEN 190 micrograms intravitreal implant in applicator for the prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment (NIPU). In the United Kingdom, a NICE recommendation for funding signifies that the country’s National Health Service (NHS) will pay for ILUVIEN prescriptions for the treatment of NIPU as part of its offering.

  • GlobeNewswire

    Three-Year Clinical Trial Results Support ILUVIEN® Launch in Europe for the Prevention of Relapse in Recurrent Non-Infectious Uveitis Affecting the Posterior Segment

    Alimera Sciences, Inc. (ALIM) (“Alimera”), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces three-year follow-up data from the Phase 3 clinical trial for ILUVIEN 190 micrograms intravitreal implant in applicator, for the prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIPU). The data will support the Company’s planned launch of ILUVIEN for the NIPU indication in Europe during the second half of 2019.